Lymphoma
Also known as: Non-Hodgkin lymphoma
Methodology & AI Transparency ⓘ
Lymphoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Lymphoma is a cancer of a part of the immune system called the lymph system.
- 2 Real-world patient consensus: Synonyms for Lymphoma (C85.90): Non-Hodgkin lymphoma (Cancer & Oncology).
- 3 Typical cash cost range: Primary evaluation for Lymphoma incorporates tissue biopsy with in Lymphoma (C85.90: histopathology) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Lymphoma: Comprehensive Metabolic & in Lymphoma (C85.90: Organ Function Panel) (Preserved renal/hepatic clearance (C85.90)) and Pathology / Molecular in Lymphoma (C85.90: Genomic Staging).
Ask our AI Specialists anything about Lymphoma
What Is Lymphoma?
Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease . The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in cancer & oncology, Lymphoma (C85.90) involves somatic oncogenic driver in Lymphoma (C85.90: mutations). Cross-referenced with NIH MeSH (Lymphoma), progression correlates with shifts in Comprehensive Metabolic & in Lymphoma (C85.90: Organ Function Panel) (Preserved renal/hepatic clearance (C85.90)).
Common Symptoms & Clinical Signs
- • Swollen, painless lymph nodes in the neck, armpits or groin
- • Unexplained weight loss
- • Presentation of Lymphoma (C85.90): abnormality detected early in Lymphoma (C85.90: on age-appropriate screening)
- • Secondary Lymphoma clinical sign: persistent painless lump, in Lymphoma (C85.90: non-healing ulcer/mole change,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Lymphoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C85.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Lymphoma (C85.90: Organ Function Panel) | Preserved renal/hepatic clearance (C85.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Lymphoma (C85.90: Genomic Staging) | Guideline-concordant surveillance (C85.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Lymphoma (C85.90: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C85.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lymphoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Gallium Citrate Ga-67 Gallium Citrate Ga-67 Generic • RxCUI RXN-69945180-1786 | FDA Prescription Therapeutic Agent | 89% | $0.5500 | $ 30.78 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lymphoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden: What a 258-Participant Study Found These updated data support therapeutic similarity of CT-P10 and rituximab and support the use of CT-P10 single-drug treatment for previously untreated LTBFL. Clinical lymphoma, myeloma & leukemia • 2022-02-15 • Phase III Randomized Trial | N = 258 | 93/100 | PMID 34686445 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Registered in the U.S. ClinicalTrials.gov Registry (NIH NLM) • 2013-03-04 • Completed Human Clinical Trial (NCT) | N = 23 | 89/100 | PMID NCT01030536 ↗ |
| Can This Approach Help? Inside the Latest Research on Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Improved long-term efficacy with R 2 versus R-placebo and manageable safety with R 2 were observed in patients with FL, including those 70 years and older. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-06-15 • Phase III Randomized Trial | N = 66 | 88/100 | PMID 41990300 ↗ |
| Can This Approach Help? Inside the Latest Research on Proof of concept of physiologically based how the body absorbs the medicine How the body absorbs the medicine parameter prediction as well as predictive performance of the model proofed to be comparable to a separately developed population how the body absorbs the medicine model with 13% deviation in... British journal of haematology • 2024-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38494194 ↗ |
| Can This Approach Help? Inside the Latest Research on Ibrutinib added to standard conditioning and as maintenance therapy following There were 4 fatalad verse events in the ibrutinib arm due to infection. Leukemia & lymphoma • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40632607 ↗ |
Lymphoma Patient Community & “People Like Me” Threads
Filter Lymphoma community threads and patient logs by age, biological sex, dosage, and treatment duration.